ClinicalTrials.gg
RecruitingNCT05106036PCOTUpdated Dec 3, 2025

Preventing Cognitive Decline by Reducing BP Target Trial

An interventional study of Clinical Support Decision Tool in Cognitive Decline, Blood Pressure and Hypertension, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Cognitive Dysfunction by University of Texas Southwestern Medical Center — 5 open to participants now, 5 under way, none of them phase 3. Cognitive Dysfunction · University of Texas Southwestern Medical Center.

Planned enrollment
Largest of 10
4,000 · median 55
Started
2022
with 1 other
No phase
6 of 11
2 open now
Registered
5th of 11
by date

Among the 11 studies in Cognitive Dysfunction by University of Texas Southwestern Medical Center, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 with no phase, and was the 5th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

5 of the 11 studies in Cognitive Dysfunction by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cognitive Dysfunction by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The PCOT study is a multi-site randomized trial of patients 70 years or older with high BP. The main goal of the study Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is to conduct a large pragmatic clinical trial (PCT) to test the hypothesis that patients who receive care with a combination of clinical decision support (CDS) and team-based care delivered in primary care practices will have better blood pressure control and a lower incidence of mild cognitive impairment and dementia than patients receiving usual medical care. Patients will be recruited from UT Southwestern Medical Center and Parkland Health \& Hospital System.

Read the detailed description

Aim 1 The main aim is to compare the effects of intensive BP intervention between the intervention and usual care arm on the rate of change in TICS-m per year. The investigators will recruit 4,000 patients over 70 years of age with BP >130/80 mmHg from 2 diverse health systems and randomize patients within each health system to usual care or to a combination of care with clinical decision support, practice facilitators and Pharm Ds to lower home BP to \< 130/80 mmHg. The primary outcome of this trial will be development cognitive decline as determined by a decrease in TICS-m scores from baseline. As a secondary outcome, the investigators will also measure the development of mild cognitive impairment or dementia in a subset of patients who show a decline of ≥3 points through adjudication.

Aim 2a Determine the potential harms of intensive lowering BP. The investigators aim to recruit 4,000 study participants and compare the effects of lowering home BP below 130/80 mmHg with usual care on hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, falls, fractures, hypotension, electrolyte abnormalities and acute kidney injury. The investigators will capture measures of adherence and health care resource utilization. The investigators will assess QOL in 4,000 patients. The investigators will capture possible harms of lowering BP below 130/80 mmHg. The investigators have chosen clinical outcomes of relevance to all the stakeholders based on prior experience on pragmatic clinical trials and our prior experience in ICD-Pieces. Outcomes will be captured from the telephone assessment by study personnel and electronic health records and/or claims data and reflecting possible harms from all participants will include hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury. There will also be capture of adherence by pharmacy refill data. The investigators will capture BP readings from each visit. The investigators will also capture number of encounters with the health system as a measure of health care utilization.

Aim 2b Determine the impact of intensive BP management on QOL. Determine the impact of intensive BP management on QOL. Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually after the administration of the TICS-m.

03

Conditions studied

  • Cognitive Decline
  • Blood Pressure
  • Hypertension
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High BP defined as at least 1 BP readings of SBP >= 130 or DBP >=80 during the 24 months prior to enrollment
  • Clinic visit with primary care provider within the last 24 months
  • Ability to write and speak English or Spanish
  • 70 years of age or older
  • Ability to understand and willingness to provide
  • Owns a smartphone

Exclusion criteria

Exclusion Criteria:

  • Blood pressure consistently \<130/80 mmHg
  • Presence of dementia, Alzheimer's disease, or significant neurological disease
  • Major and unstable heart disease (e.g., acute heart failure (systolic or diastolic), acute on chronic heart failure (systolic or diastolic), acute coronary syndrome or cardiac arrest, liver or renal transplantation
  • Under 70 years of age
  • Inability to write or speak English or Spanish
  • Chronic kidney disease stage 5 or ESKD
  • Chemotherapy
  • Any conditions judged by the medical providers to contraindicate participation due to risk to patient safety or lack of adherence
  • Expected under a year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
4,000 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .

    Other: Clinical Support Decision Tool

  • No intervention
    Usual Care Arm

    Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.

Interventions

  • OtherClinical Support Decision Tool

    Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.

06

What researchers measure

Primary outcomes

  1. Cognitive Decline

    Rate of change in Modified Telephone Interview for Cognitive Status (TICS-m) test between study arms. The test has scores ranging from 0 to 42 with higher values indicating better cognitive status.

    Time frame: 4 years

Secondary outcomes

  1. Mild Cognitive Decline or Dementia

    Development of mild cognitive decline or dementia as determined through adjudication from cognitive experts between study arms

    Time frame: 4 years

Other outcomes

  1. Number of Pharmacy Refills

    Between the two groups

    Time frame: 4 years

  2. Change in quality of life assessment

    Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually. The investigators will assess change in quality of life across the four years between the two groups. The Global Health instrument has scores ranging from 4 to 20 for their Mental and Physical Health Items with higher values indiciating better global health.

    Time frame: 4 years

  3. Number of encounters within the participant's health system

    The number of encounters within the participant's respective health system between the two groups will be used to assess healthcare utilization.

    Time frame: 4 years

  4. Systolic and Diastolic BP Readings

    Between the two groups

    Time frame: 4 years

  5. Combination Pill Use

    Between the two groups

    Time frame: 4 years

  6. BP Above 130/80

    Between the two groups

    Time frame: 4 years

  7. Count of individuals who experience any of the following safety events: hospitalizations and emergency room visits

    Total number of hospitalizations and emergency room visits related to cardiovascular events, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury between the two groups.

    Time frame: 4 years

  8. Number of reported deaths

    Count of the number of reported deaths between the two groups

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2026, 49 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 49 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Nov 3, 2021
StartActual
Jul 11, 2022
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05106036
Collaborators
National Institute on Aging (NIA), Duke University, Parkland Health and Hospital System
Responsible party
Miguel Vazquez (Professor, Clinical Director, Division of Nephrology, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Nov 3, 2021
Start date
Jul 11, 2022
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Dec 3, 2025

Study contacts

Venkatraghavan Sundaram, Ph.D.
Contact
venkatraghavan.sundaram@phhs.org
214-590-3848
Miguel Vazquez, MD
Contact
miguel.vazquez@utsoutwestern.edu
214-648-3442

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion